Evidence map›Paper›PMID 41970281›Full record

ArticleClinical & translational immunology2026

A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors.

Bryan Gardam, Eunwoo Nam, Paris M Kollis, Jasmine Kilyen-Coles, S Lenin, Briony L Gliddon, Melinda N Tea, Stuart M Pitson, Michael P Brown, Lisa M Ebert and 1 more

Abstract read
In one paragraph

Article in Clinical & translational immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bryan GardamSchool of Medicine, College of Health Adelaide University Adelaide SA Australia.ORCID https://orcid.org/0000-0001-6612-9331
Eunwoo NamSchool of Medicine, College of Health Adelaide University Adelaide SA Australia.
Paris M KollisSchool of Medicine, College of Health Adelaide University Adelaide SA Australia.
Jasmine Kilyen-ColesSchool of Medicine, College of Health Adelaide University Adelaide SA Australia.
S LeninMolecular Therapeutics Laboratory, Centre for Cancer Biology, College of Health Adelaide University Adelaide SA Australia.
Briony L GliddonMolecular Therapeutics Laboratory, Centre for Cancer Biology, College of Health Adelaide University Adelaide SA Australia.
Melinda N TeaMolecular Therapeutics Laboratory, Centre for Cancer Biology, College of Health Adelaide University Adelaide SA Australia.
Stuart M PitsonSchool of Medicine, College of Health Adelaide University Adelaide SA Australia.
Michael P BrownSchool of Medicine, College of Health Adelaide University Adelaide SA Australia.
Lisa M EbertSchool of Medicine, College of Health Adelaide University Adelaide SA Australia.
Tessa GargettSchool of Medicine, College of Health Adelaide University Adelaide SA Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Glioblastoma is characterised by poor survival with few treatment advances for over 20 years. Immunotherapies, which have transformed treatment of other cancers, have been difficult to apply to glioblastoma because of its highly immune-suppressive microenvironment, and there is a growing appreciation that the disease also induces a global suppression of the systemic immune system. However, immunotherapy research is hampered by the lack of detailed characterisation of the whole immune system in murine brain tumor models, with studies until now having focussed mainly on tumor-infiltrating immune cells. Methods: Here, we have studied common murine models of intracranial brain tumors by using high-parameter flow cytometry and tissue immunofluorescence staining to fully characterise immune cells in the brain, draining lymph node, spleen and bone marrow. Results: The highly immune-compromised NSG mouse models were striking in their many immune perturbations, which extended beyond the known deficits in lymphocytes. Immunocompetent tumor models had significant changes in brain-resident immune cells compared to controls, as expected; however, systemic effects were also observed with significant reductions in subsets of monocytes, macrophages and dendritic cells in the spleen and increases in bone marrow. Conclusion: Our extensive and quantitative characterisation of the immune system in murine models of glioblastoma will allow for a better-informed selection of models and advance the search for new immune-based treatments for this deadly disease.

Indexed as

brain tumorglioblastomaimmunphenotypingmurine models

Identifiers

PMID41970281
PMCPMC13065875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.